ASCO 2021 | Cardiac safety in the APHINITY study
It is known that trastuzumab increases the incidence of cardiac events in patients with early breast cancer. In this interview, Evandro de Azambuja, MD, PhD, L’Universite Libre de Bruxelles, Brussels, Belgium, analyzes the cardiac safety of dual blockade with pertuzumab and trastuzumab in patients enrolled in APHINITY (NCT01358877). Dual blockade does not increase the risk of cardiac events compared to platinum agents and trastuzumab alone. In patients with cardiovascular risk factors, non-anthracycline-based chemotherapy regimens should be considered. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Evandro de Azambuja, MD, PhD, has received honoraria and advisory board roles from Roche/GNE, Novartis, Seattle Genetics, Zodiacs, Lilly, Libbs and Pierre Fabre; travel grants from Roche/GNE and GSK/Novartis; research grants for his institute (IJB) from Roche/GNE, Astra-Zeneca, Novartis, and Servier.
